Abstract Details

Title Electrical Impedance Myography via the Myolex mScan as an ALS Disease Progression Biomarker: An Update From the ElectricALS Study

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-020

Objective Test the feasibility and reliability of at-home Electrical Impedance Myography (EIM) measurements collected via the Myolex mScan® device in individuals with amyotrophic lateral sclerosis (ALS), and to assess its potential as a biomarker of disease progression.

Background Identifying sensitive tools to assess new ALS therapies remains a major challenge due to the disease's heterogeneous presentation. Current standardized instruments, such as the ALS Functional Rating Scale-Revised (ALSFRS-R), are limited by subjectivity and may lack sensitivity to detect subtle changes. As an alternative, EIM is a technology that assesses muscle physiology in a non-invasive and painless way, providing a quantitative measurement for tracking disease progression.

Design/Methods This ongoing prospective cohort study enrolls ALS participants across six U.S. centers. The Myolex mScan® is a novel portable EIM device that enables at-home assessments, thereby increasing data collection frequency and reducing participant burden. Over eight months, EIM parameters for six muscle groups are assessed using the mScan device twice-weekly by a study partner. At-home ALSFRS-R scores are also performed weekly. Participants attend three clinic visits for handheld dynamometry, EIM, and ALSFRS-R assessments. Changes in EIM parameters and their relationship with functional measures over time are being analyzed.

Results Data from five participants using the device for over two months show that at-home EIM phase values at 447kHz for selected muscles in upper and lower extremities shows a declining trend. When compared with the at-home ALSFRS-R data, both EIM parameters and questionnaire scores have been decreasing over time. Although, additional data is needed to further evaluate the relationship between these measures.

Conclusions Preliminary analyses of at-home EIM show that the technology is both feasible and sensitive to ALS-associated declines in muscle health. With continued data collection, we will be able to determine EIM's value as a sensitive and meaningful biomarker of ALS progression for at-home use in therapeutic clinical trials.

Authors/Disclosures
Giulia I. Cenci, MD (BIDMC) PRESENTER	Dr. Cenci has nothing to disclose.
Buket Sonbas Cobb, PhD	Dr. Sonbas Cobb has nothing to disclose.
Mia T. Hemme	Ms. Hemme has nothing to disclose.
Ajitesh Nanda (Beth Israel Deaconess Medical Center)	Ajitesh Nanda has nothing to disclose.
Askhat Mukushev (Beth Israel Deaconess Medical Center)	Askhat Mukushev has nothing to disclose.
Teresa Capella	Teresa Capella has nothing to disclose.
Seward B. Rutkove, MD, FAAN	Dr. Rutkove has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Myolex, Inc. Dr. Rutkove has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neuorlogy . The institution of Dr. Rutkove has received research support from NIH. The institution of Dr. Rutkove has received research support from NASA. The institution of Dr. Rutkove has received research support from Blavatnik Family Foundation. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received intellectual property interests from a discovery or technology relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received publishing royalties from a publication relating to health care. Dr. Rutkove has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.

��ɫ��

��ɫ��